ProFibrix B.V.: Series A €8.5M

ProFibrix (Netherlands) a biotech company focused on fibrinogen-based products to stop surgical hemmoraging and initiate tissue repair, has closed a €8.5M Series A round. The deal was led by Index Ventures.

Regado Biosciences, Inc.: Series C $23M

Regado Biosciences (Durham, NC) a biopharmaceutical company with a platform oligonucleotide drug-antidote pairing system focused upon the anticoagulant market has closed a $23M Series C financing. The deal was led by Caxton Advantage Life Sciences, Domain Associates, Quaker BioVentures and Aurora Funds.

Coapt Systems, Inc.: Series E $22.6M

Coapt Systems (Palo Alto, CA) develops bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures raised $22.6M in a Series E financing. The deal was led by Global Life Science Ventures and Easton Capital other participants included Alta Partners, Asset Management Company, Canaan Partners, Millennia Partners and Foundation Medical Partners.

CoDa Therapeutics, Inc.: Series A $20M

CoDa Therapeutics (New Zeland) -based drug company focused on Nexagon, a wound care and tissue repair therapeutic, raised a $20M Series A financing. The round was led by Domain Associates and GBS Venture Partners.

Advanced BioHealing, Inc.: Series C $25.5M

Advanced BioHealing (La Jolla, CA) a regenerative medicine, artificial skin tissue and wound healing company raised $25.5M in Series C funding.The deal was led by Safeguard Scientific and was accompanied by Channel Medical Partners, Red Abbey Venture Partners, Canaan Partners and Wheatley Partners.